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On the Cover: Ixodes scapularis (also known as the blacklegged 
or deer tick), which transmits the agent of Lyme disease, Borrelia 
burgdorferi, to humans.
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Surveillance for Lyme Disease — United States, 1992–2006
Rendi Murphree Bacon, MS, Kiersten J. Kugeler, MPH, Paul S. Mead, MD
Division of Vector-Borne Infectious Diseases, National Center for Zoonotic Vector-Borne and Enteric Diseases
Abstract
Problem/Condition: Lyme disease is a multisystem disease that occurs in North America, Europe, and Asia. In the 
United States, the etiologic agent is Borrelia burgdorferi sensu stricto, a spirochete transmitted to humans by infected 
Ixodes scapularis and I. pacificus ticks. The majority of patients with Lyme disease develop a characteristic rash, erythema 
migrans (EM), accompanied by symptoms of fever, malaise, fatigue, headache, myalgia, or arthralgia. Other manifesta-
tions of infection can include arthritis, carditis, and neurologic deficits. Lyme disease can be treated successfully with 
standard antibiotic regimens.
Reporting Period: 1992–2006.
Description of System: U.S. health departments report cases of Lyme disease voluntarily to CDC as part of the National 
Notifiable Disease Surveillance System. Variables collected include patient age, sex, race, county and state of residence, 
date of illness onset, and reported signs and symptoms.
Results: During 1992–2006, a total of 248,074 cases of Lyme disease were reported to CDC by health departments 
in the 50 states, the District of Columbia, and U.S. territories; the annual count increased 101%, from 9,908 cases in 
1992 to 19,931 cases in 2006. During this 15-year period, 93% of cases were reported from 10 states (Connecticut, 
Delaware, Massachusetts, Maryland, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island, and Wisconsin). 
Incidence was highest among children aged 5–14 years, and 53% of all reported cases occurred among males. More 
than 65% of patients with EM had illness onset in June and July, compared with 37% of patients with arthritis.
Interpretation: Lyme disease is the most commonly reported vectorborne illness in the United States. The geographic 
distribution of cases is highly focused, with the majority of reported cases occurring in the northeastern and north-central 
states. During 1992–2006, the number of reported cases more than doubled. A disproportionate increasing trend was 
observed in children and in young males compared with other demographic groups.
Public Health Action: The results presented in this report underscore the continued emergence of Lyme disease and 
the need for tick avoidance and early treatment interventions. Public health practitioners can use the data presented in 
this report to target prevention campaigns to populations with increasing incidence (i.e., children and young males).
Introduction
Lyme disease was first described in 1977 following investiga-
tion of a cluster of arthritis cases among children living near 
Lyme, Connecticut (1). Further study indicated that arthritis 
was a late manifestation of a multisystem, tick-transmitted 
disease. In 1981, a bacterial spirochete, Borrelia burgdorferi, 
was identified in Ixodes scapularis (2) and later demonstrated 
to be the etiologic agent of Lyme disease (3,4).
B. burgdorferi occurs naturally in reservoir hosts, including 
mice, squirrels, shrews, and other small vertebrates (5). Ixodes 
scapularis and I. pacificus (also referred to as blacklegged or deer 
ticks) become infected with B. burgdorferi while feeding on 
the blood of natural reservoir hosts. During subsequent blood 
meals, the ticks can transmit infection among reservoir hosts or 
to incidental hosts, including humans. Although deer are not 
infected with B. burgdorferi, they play a role in transporting 
ticks and maintaining tick populations.
In humans, infection with B. burgdorferi can result in derma-
tologic, musculoskeletal, neurologic, or cardiac abnormalities 
(6–8). In approximately 70%–80% of cases, patients develop 
a characteristic rash, erythema migrans (EM), within 30 
days of infection with B. burgdorferi. EM is a red expanding 
rash, with or without central clearing, which often is accom-
panied by symptoms of fatigue, fever, headache, mild stiff 
neck, arthralgia, or myalgia. Within days or weeks, untreated 
infection can spread to other parts of the body, causing more 
serious neurologic conditions (e.g., meningitis, radiculopathy, 
and facial palsy) or cardiac abnormalities (e.g., carditis with 
Corresponding author: Paul S. Mead, MD, Division of Vector-Borne 
Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases, CDC, 3150 Rampart Rd., MS P-O2, Fort Collins, 
CO 80521. Telephone: 970-221-6474; Fax: 970-221-4257; E-mail; 
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atrioventricular heart block). Over a period of months or 
years, untreated infection can lead to mono- or oligoarticular 
arthritis, peripheral neuropathy, or encephalopathy.
Lyme disease is diagnosed on the basis of physician-observed 
clinical manifestations and a history of probable exposure to 
infected ticks (8). Laboratory tests are neither suggested nor 
required to confirm diagnosis for patients with recent onset 
(2–3 weeks) of a characteristic EM rash (9). However, positive 
results of recommended two-tiered serologic testing (10) can 
provide confirmation of infection in patients with musculo-
skeletal, neurologic, or cardiac symptoms. Testing methods 
that have not been adequately validated can be misleading 
(11) and are not recommended (12).
The majority of infections can be cured with use of recom-
mended antimicrobials. Patients with physician-diagnosed EM 
can be treated with oral doxycycline, amoxicillin, or cefuroxime 
axetil (7,8). Patients with other manifestations of Lyme disease 
are treated with either oral or intravenous antimicrobials (e.g., 
ceftriaxone), depending on the specific clinical condition.
Measures to prevent Lyme disease and other tickborne infec-
tions include avoiding tick-infested areas when possible, using 
insect repellents containing 20%–30% DEET (N,N-diethyl-
m-toluamide) on exposed skin and clothing, and performing 
daily self-examination for ticks (13). Tick abundance can be 
reduced around private homes and in recreational areas by 
removing brush and leaf litter, creating a buffer zone of wood 
chips or gravel between forests and lawn, applying acaricides, 
and excluding deer (13,14). Tickborne illness can be mitigated 
by prompt and proper tick removal and by recognizing and 
seeking treatment for early signs of illness (8,15,16). A single 
dose of doxycycline should be considered for prophylaxis of 
Lyme disease in persons aged >8 years who have been bitten 
by a nymph or adult I. scapularis or I. pacificus tick in an area 
in which at least 20% of ticks are thought to be infected with 
B. burgdorferi (8). The tick must have been attached for ≥36 
hours and prophylactic antibiotic administered within 72 hours 
of tick removal (8).
With the cooperation of state and local health depart-
ments, CDC initiated surveillance for Lyme disease in 1980; 
the first summary of 226 cases was published in 1981 (17). 
Before 1991, Lyme disease surveillance case definitions and 
reporting practices varied among states and between states 
and CDC. Standardized surveillance and reporting for Lyme 
disease began in 1991 after the Council of State and Territorial 
Epidemiologists (CSTE) designated Lyme disease as a nation-
ally notifiable disease and published a standardized surveillance 
case definition* (18). This report describes the characteristics 
and distribution of Lyme disease cases reported in the United 
States during 1992–2006, providing 15-year trends and the 
frequency of reported symptoms. In addition, it details differ-
ences between cases reported from within and outside of the 
10 states (Connecticut, Delaware, Maryland, Massachusetts, 
Minnesota, New Jersey, New York, Pennsylvania, Rhode Island, 
and Wisconsin) in which Lyme disease is highly endemic† (19). 
These results underscore the continued emergence of Lyme 
disease and provide a basis for targeting prevention campaigns 
to populations with increasing incidence.
Methods
Surveillance Case Definitions
During 1991–1996, a case of Lyme disease was defined for 
national surveillance purposes as 1) physician-diagnosed EM 
of ≥5 cm in diameter or 2) at least one objective late manifesta-
tion (i.e. musculoskeletal, cardiovascular, or neurologic) with 
laboratory confirmation of infection with B. burgdorferi (18). 
Laboratory confirmation required 1) isolation of B. burgdor-
feri from clinical specimens, 2) demonstration of diagnostic 
levels of immunoglobulin M (IgM) and immunoglobulin G 
(IgG) antibodies to B. burgdorferi in serum or cerebrospinal 
fluid (CSF), or 3) significant change in IgM or IgG antibody 
response in paired serum samples. In 1997, CSTE and CDC 
implemented a revised surveillance case definition on the basis 
of the availability of improved serologic testing (20). Clinical 
criteria were not changed; however, laboratory confirmation 
was modified to require 1) isolation of B. burgdorferi from a 
clinical specimen or 2) demonstration of diagnostic levels of 
IgM or IgG antibodies to B. burgdorferi in serum or CSF. A 
two-test approach (a sensitive enzyme immunoassay or immu-
nofluorescence antibody assay followed by Western blot) was 
recommended but not required (10).
Data Sources
U.S. state and territorial health departments report cases 
of Lyme disease voluntarily to CDC as part of the National 
Notifiable Disease Surveillance System (NNDSS). Provisional 
data are transmitted to CDC weekly using the National 
Electronic Telecommunications System for Surveillance, 
* The Lyme disease surveillance case definition was developed to standardize 
national public health surveillance and reporting of Lyme disease cases; it is 
not meant to be used as absolute criteria for clinical diagnosis.
† In 2000, these 10 states were defined as Healthy People 2010 (HP2010) Lyme 
disease reference states. A Healthy People 2010 goal (objective no. 14-8) is 
to reduce Lyme disease to 9.7 new cases per 100,000 population in the 10 
HP2010 reference states (19) through the implementation of community-based 
prevention programs, host-targeted acaricides to reduce the numbers of vector 
ticks, and appropriate use of Lyme disease vaccine. However, the only vaccine 
approved by the Food and Drug Administration for use against Lyme disease 
in humans was removed from sale by the manufacturer in February 2002 citing 
low demand, greatly reducing the possibility of achieving this objective.
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and final data are published annually in CDC’s Summary of 
Notifiable Diseases (available at http://www.cdc.gov/mmwr). 
State or local health departments are responsible for ensuring 
that cases reported to CDC meet the case definition.
This report is based on data for all Lyme disease cases reported 
to CDC for 1992–2006.§ During this 15-year period, state 
health officials used various methods to ascertain cases, includ-
ing provider-initiated passive surveillance, laboratory-based 
surveillance, and enhanced or active surveillance. Basic demo-
graphic data (e.g., age, sex, race, and county of residence) were 
available for >90% of reported cases; however, information 
specific to Lyme disease (e.g., county of exposure, symptoms 
and signs, antibiotic treatment, and laboratory results) was 
incomplete. For example, only 61% of case reports contained 
data for reported signs and symptoms.
Analyses
Annual U.S.-, state-, county-, sex-, and age group–specific 
incidence rates per 100,000 population were calculated 
using U.S. Census Bureau population estimates for July 1 
for each year of the reporting period (1992–2006). Analyses 
of symptom data were restricted to case reports for which at 
least one symptom was coded as “yes” (n = 150,829 records). 
Characteristics of cases reported from the 10 HP2010 refer-
ence states were compared with cases reported from all other 
(non-HP2010) states and territories.
Results
U.S. Case Counts and Rates
During 1992–2006, a total of 248,074 Lyme disease cases 
were reported to CDC. Although annual counts fluctuated by 
as much as 57% from year to year, the overall trend indicates 
a steady increase in the number of reported cases (Figure 1). 
During the 15-year study period, the number of cases reported 
increased 101%, from 9,908 cases in 1992 to 19,931 cases in 
2006.
State Rates
The 15-year mean annual rate for all states ranged from <0.01 
cases per 100,000 population in Montana and Colorado to 
73.6 cases per 100,000 population in Connecticut (median: 0.5 
cases) (Table 1). The 10 HP2010 reference states accounted for 
229,782 cases, representing 92.6% of overall cases and at least 
88% of cases reported in any single year. Reported annual rates 
§ Although data for 1991 were available, these data were excluded from the analysis 
because certain states reported aggregate case counts rather than information 
for individual case reports.
FIGURE 1. Number* of reported Lyme disease cases, by year 







1992 1994 1996 1998 2000 2002 2004 2006
Year
* N = 248,074.
for seven HP2010 reference states (Maryland, Massachusetts, 
Minnesota, New Jersey, New York, Pennsylvania, and 
Wisconsin) were relatively stable during 1992–2006. Annual 
rates were more variable in three states (Connecticut, Delaware, 
and Rhode Island), in part because of changes in surveillance 
practices. In Connecticut, annual rates per 100,000 popula-
tion increased from 53.7 cases in 1992 to 133.9 cases in 2002; 
in 2003, the rate decreased to 40.3 cases. In Delaware, the 
number of cases increased from 339 in 2004 to 646 in 2005, 
boosting the annual rate per 100,000 population from 40.9 to 
76.7 cases. The annual rate per 100,000 population reported in 
Rhode Island increased from 27.5 cases in 1992 to 68.5 cases 
in 2003, then declined to 23.1 cases in 2004 and 3.6 cases in 
2005; 28.9 cases were reported in 2006.
County Rates
County of residence was provided for 243,430 (98.1%) 
cases. The mean number of counties reporting at least one 
case of Lyme disease was 714 (range: 625–796). In all years, 
the percentage of counties reporting at least one case was 
>75 in six states (Connecticut, Delaware, Massachusetts, 
Maryland, New Jersey, and Rhode Island). In contrast, during 
1992–2006, the percentage of counties reporting at least one 
case increased from 33% to 74% in Minnesota, from 79% to 
97% in Pennsylvania, and from 76% to 97% in Wisconsin. 
In New York, the percentage of counties reporting at least one 
case ranged from 61% to 85%, with no obvious increasing or 
decreasing temporal trend.
The 15-year average county-specific rate for counties report-
ing at least one case during 1992–2006 ranged from <0.01 
cases per 100,000 population in Honolulu County, Hawaii, 
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TABLE 1. Annual rate* of Lyme disease, by state/area and year — United States, 1992–2006
Year
State/Area 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Average
Alabama 0.2 0.1 0.1 0.3 0.2 0.3 0.6 0.5 0.1 0.2 0.3 0.2 0.1 0.1 0.2 0.2
Alaska 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.3 0.3 0.5 0.5 0.5 0.6 0.5 0.2
Arizona 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.2 0.1
Arkansas 0.8 0.3 0.6 0.4 1.1 1.1 0.3 0.3 0.3 0.2 0.1 0.0 0.0 0.0 0.0 0.4
California 0.8 0.4 0.2 0.3 0.2 0.5 0.4 0.4 0.3 0.3 0.3 0.2 0.1 0.3 0.2 0.3
Colorado 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
Connecticut† 53.7 41.3 62.1 47.4 95.0 70.3 104.9 98.0 110.6 104.8 133.9 40.3 38.6 51.7 51.0 73.6
Delaware† 31.7 20.4 15.0 7.8 23.8 14.8 10.4 22.2 21.2 19.1 24.1 26.0 40.9 76.8 56.5 27.4
District of Columbia 0.5 0.4 1.6 0.5 0.6 1.9 1.5 1.2 1.9 2.9 4.3 2.4 2.8 1.7 10.7 2.3
Florida 0.2 0.2 0.2 0.1 0.4 0.4 0.5 0.4 0.3 0.3 0.5 0.3 0.3 0.3 0.2 0.3
Georgia 0.7 0.6 1.8 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.3
Hawaii 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Idaho 0.2 0.2 0.3 0.0 0.2 0.3 0.6 0.2 0.3 0.4 0.3 0.2 0.4 0.1 0.5 0.3
Illinois 0.4 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.3 0.4 0.6 0.7 1.0 0.9 0.4
Indiana 0.4 0.6 0.3 0.3 0.6 0.6 0.7 0.4 0.4 0.4 0.3 0.4 0.5 0.5 0.4 0.5
Iowa 1.2 0.3 0.6 0.6 0.7 0.3 0.9 0.8 1.2 1.2 1.4 2.0 1.7 3.0 3.3 1.3
Kansas 0.7 2.1 0.7 0.9 1.4 0.2 0.5 0.6 0.6 0.1 0.3 0.2 0.1 0.1 0.1 0.6
Kentucky 0.8 0.4 0.6 0.4 0.7 0.5 0.7 0.5 0.3 0.6 0.6 0.4 0.4 0.1 0.2 0.5
Louisiana 0.2 0.1 0.1 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.0 0.2
Maine 1.3 1.5 2.7 3.6 5.1 2.7 6.3 3.3 5.6 8.4 16.9 13.4 17.1 18.7 25.6 8.8
Maryland† 3.7 3.6 6.8 9.0 8.8 9.7 12.9 17.4 13.0 11.3 13.6 12.6 16.1 22.1 22.2 12.2
Massachusetts† 3.7 2.5 4.1 3.1 5.3 4.8 11.4 12.8 18.2 18.2 28.1 23.8 23.8 36.3 22.3 14.5
Michigan 0.4 0.2 0.3 0.1 0.3 0.3 0.2 0.1 0.2 0.2 0.3 0.1 0.3 0.6 0.6 0.3
Minnesota† 4.4 3.1 4.6 4.5 5.4 5.5 5.5 5.9 9.4 9.3 17.3 9.4 20.1 17.9 17.7 9.3
Mississippi 0.0 0.0 0.0 0.6 0.9 1.0 0.6 0.1 0.1 0.3 0.4 0.8 0.0 0.0 0.1 0.3
Missouri 2.9 2.1 1.9 1.0 1.0 0.5 0.2 1.3 0.9 0.7 0.7 1.2 0.4 0.3 0.1 1.0
Montana 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
Nebraska 1.4 0.4 0.2 0.4 0.3 0.1 0.2 0.7 0.3 0.2 0.4 0.1 0.1 0.1 0.6 0.4
Nevada 0.1 0.4 0.1 0.4 0.1 0.1 0.3 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.2 0.2
New Hampshire 4.0 1.3 2.7 2.4 4.1 3.3 3.8 2.3 6.8 10.3 20.5 14.8 17.4 20.3 46.9 10.7
New Jersey† 8.8 10.0 19.4 21.4 27.3 25.3 23.6 21.1 29.2 23.8 27.4 33.4 31.1 38.6 27.9 24.6
New Mexico 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.1
New York† 19.1 15.5 28.6 24.5 29.2 18.3 25.6 24.2 22.8 21.4 28.9 28.1 26.4 28.8 23.1 24.3
North Carolina 1.0 1.2 1.1 1.2 0.9 0.5 0.8 1.0 0.6 0.5 1.7 1.9 1.4 0.6 0.4 1.0
North Dakota 0.2 0.3 0.0 0.0 0.3 0.0 0.0 0.2 0.3 0.0 0.2 0.0 0.0 0.5 1.1 0.2
Ohio 0.3 0.3 0.4 0.3 0.3 0.4 0.4 0.4 0.5 0.4 0.7 0.6 0.4 0.5 0.4 0.4
Oklahoma 0.8 0.6 3.1 1.9 1.3 1.4 0.4 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.7
Oregon 0.4 0.3 0.2 0.6 0.6 0.6 0.6 0.5 0.4 0.4 0.3 0.5 0.3 0.1 0.2 0.4
Pennsylvania† 9.8 9.0 11.9 13.0 23.4 18.2 23.0 23.2 19.1 22.8 32.4 46.4§ 32.2 34.6 26.1 23.0
Rhode Island† 27.5 27.3 47.4 34.9 54.1 44.8 79.9 55.1 64.2 48.2 79.7 68.5 23.1 3.6 28.9 45.8
South Carolina 0.1 0.3 0.2 0.5 0.2 0.1 0.2 0.2 0.6 0.2 0.6 0.4 0.5 0.4 0.5 0.3
South Dakota 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.1
Tennessee 0.6 0.4 0.3 0.5 0.5 0.8 0.9 1.1 0.5 0.5 0.5 0.3 0.3 0.1 0.3 0.5
Texas 0.6 0.3 0.3 0.4 0.5 0.3 0.2 0.4 0.4 0.4 0.6 0.4 0.4 0.3 0.1 0.4
Utah 0.3 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.2 0.1
Vermont 1.6 2.1 2.8 1.5 4.4 1.4 1.9 4.4 6.6 2.9 6.0 7.0 8.1 8.7 16.8 5.1
Virginia 1.9 1.5 2.0 0.8 0.9 1.0 1.1 1.8 2.1 2.2 3.6 2.6 2.9 3.6 4.7 2.2
Washington 0.3 0.2 0.1 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.2
West Virginia 0.8 2.8 1.6 1.4 0.7 0.6 0.7 1.1 1.9 0.9 1.4 1.7 2.1 3.4 1.5 1.5
Wisconsin† 10.5 7.9 8.0 7.2 7.7 9.2 12.6 9.3 11.7 11.1 20.0 13.5 20.8 26.4 26.4 13.5
Wyoming 1.1 1.9 1.1 0.8 0.6 0.6 0.2 0.6 0.6 0.2 0.4 0.4 0.8 0.6 0.2 0.7
* Per 100,000 population using U.S. Census Bureau population estimates for July 1 for each year of the reporting period.
† Healthy People 2010 reference states in which Lyme disease is endemic.
§ Includes 4,722 confirmed and 1,008 suspected cases.
to 595.1 cases per 100,000 population in Nantucket County, 
Massachusetts (median: 0.7 cases per 100,000 population) 
(Figure 2). Counties with the highest average county-specific 
rate for three 5-year periods during the 15-year reporting 
period (1992–1996, 1997–2001, and 2002–2006) are pre-
sented (Table 2). Five counties ranked among the top 10 
incidence counties for each 5-year period: Windham County, 
Connecticut; Nantucket County, Massachusetts; Hunterdon 
County, New Jersey; Dutchess County, New York; and Putnam 
County, New York. The only counties outside the northeast 
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1 Nantucket County, MA 755 (55) Nantucket County, MA 669 (60) Columbia County, NY 962 (609)
2 Hunterdon County, NJ 337 (385) Columbia County, NY 639 (403) Dutchess County, NY 439 (1281)
3 Dutchess County, NY 337 (899) Dutchess County, NY 445 (1234) Nantucket County, MA 361 (36)
4 Putnam County, NY 278 (248) Hunterdon County, NJ 443 (535) Dukes County, MA 337 (52)
5 Washington County, RI 227 (262) Windham County, CT 304 (330) Hunterdon County, NJ 276 (356)
6 Middlesex County, CT 197 (290) Washington County, RI 296 (361) Greene County, NY 271 (133)
7 Washburn County, WI 182 (27) Putnam County, NY 222 (211) Cameron County, PA 239 (14)
8 Burnett County, WI 161 (23) Dukes County, MA 201 (30) Washburn County, WI 238 (39)
9 New London County, CT 156 (400) Litchfield County, CT 195 (355) Windham County, CT 220 (249)
10 Windham County, CT 130 (137) New London County, CT 183 (472) Putnam County, NY 219 (219)
* Per 100,000 population.
FIGURE 2. Average rate* of Lyme disease, by county of resi-




* Per 100,000 population.
† County of residence was available for 98.1% of cases reported during 
1992–2006.
§ During 2003, Pennsylvania reported 4,722 confirmed cases and 1,008 
suspected cases.
to rank among the top 10 counties for any 5-year period were 
Washburn County and Burnett County, Wisconsin. Because 
of marked differences in population size across counties, a 
high rate does not necessarily indicate a substantial number 
of reported cases.
Selected Demographics
Information regarding age was available for 241,931 (97.5%) 
reported cases. Reported ages ranged from <1–106 years and 
were bimodal in distribution (Figure 3). Average annual rates 
peaked among children aged 5–9 years (8.6 cases per 100,000 
population) and adults aged 55–59 years (7.8 cases per 100,000 
population). The lowest rate was reported among adults aged 
20–24 years (3.0 cases per 100,000 population).
Information about sex was available for 243,564 (99.1%) 
reported cases. Of these, 129,349 (53.1%) occurred among 
FIGURE 3. Number* of reported Lyme disease cases, by age 
group — United States, 1992–2006
0
5,000







* N = 241,931.
males, yielding an average annual rate per 100,000 popula-
tion of 6.3 cases for males and 5.4 cases for females. During 
1992–2006, rates increased disproportionately among males 
compared with females (Figure 4). This trend was most pro-
nounced among persons aged 5–19 years; rates per 100,000 
population in this age group increased 194% in males, from 
3.5 cases in 1992 to 10.3 cases in 2006, and 114% in females, 
from 2.9 cases in 1992 to 6.2 cases in 2006.
Information regarding race was available for 166,194 
(70.0%) reported cases. Of these, 156,346 (94.1%) patients 
were identified as white, 2,765 (1.7%) as black, 1,299 (0.8 %) 
as Asian/Pacific Islander, and 452 (0.3%) as American Indian/
Alaska Native.
Age and sex of persons with Lyme disease differed among 
the 10 HP2010 reference states compared with other states. 
In the reference states, the modal age was 7 years, and males 
accounted for 120,369 (53.4%) reported cases. In the remain-
ing states, the modal age was 44 years, and males accounted 
for 8,890 (49.4%) cases.
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Seasonality
Month of disease onset was available for 188,340 (75.9%) 
reported cases (Figure 5). Although cases occurred in all months 
of the year; the majority (48,413 [25.7%]) of patients had onset 
in June, July (56,507 [30.0%]), or August (22,867 [12.1%]), 
the 3 months in which ticks actively seek mammalian hosts and 
human outdoor activity is greatest. In the HP2010 reference 
states, 99,762 (56.5%) cases had onset during June or July, 
compared with 5,518 (44.2%) among non-HP2010 reference 
states. Among 150,829 cases with reported clinical features, 
seasonal variation was most pronounced for cases with EM 
(Figure 6). Approximately 67% of patients with EM had onset 
in June and July, compared with 37% of those with arthritis.
Clinical Features
Information on clinical features of illness was available 
for 150,829 (60.8%) cases. Among these, EM was reported 
for 104,387 (69.2%) cases, arthritis characterized by brief 
attacks of joint swelling for 48,272 (32.0%) cases, neurologic 
symptoms (facial palsy or cranial neuritis, radiculoneuropathy, 
lymphocytic meningitis, encephalitis, or encephalomyelitis) for 
18,157 (12.0%) cases, and second- or third-degree atrioven-
tricular block for 1,222 (0.8%) cases. More than one clinical 
manifestation was reported for 19,321 (12.8%) cases. Data on 
clinical features of cases from all states was representative of 
data on clinical features of cases from the HP2010 reference 
states. By comparison, among 7,745 cases reported from non-
HP2010 states, EM was reported less frequently (4,887 cases 
[63.0%]), and musculoskeletal, neurologic, and cardiac mani-
FIGURE 5. Number* of reported Lyme disease cases, by month 
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FIGURE 6. Percentage of symptoms reported among Lyme 
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festations were reported more frequently (3,285 cases [42.4%], 
1,442 cases [18.6%], and 100 cases [1.3%], respectively).
Temporal trends in national data indicate that the overall 
frequency of reported clinical features were generally stable over 
time (Figure 7). However, the frequency of reported symptoms 
was highly variable across the youngest age categories (Figure 8) 
and among HP2010 reference states (Table 3).
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FIGURE 7. Percentage of symptoms reported among Lyme 
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FIGURE 8. Percentage of symptoms reported among Lyme 
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TABLE 3. Number and percentage* of reported symptoms among Lyme disease patients, by state† — Healthy People 2010 (HP2010) 
reference states, 1992–2006
EM§ Arthritis Neurologic Cardiac
State No. (%) No. (%) No. (%) No. (%)
Connecticut 25,538 (74) 7,845 (23) 3,305 (10) 171 (0.5)
Delaware 846 (51) 828 (50) 263 (16) 14 (0.9)
Massachusetts 8,196 (68) 3,948 (33) 1,849 (15) 179 (1.5)
Maryland 4,908 (60) 2,919 (36) 1,738 (21) 80 (1.0)
Minnesota¶ 218 (87) 48 (19) 15 (6) 1 (0.4)
New York 33,024 (74) 10,953 (25) 4,047 (9) 362 (0.8)
Pennsylvania 17,014 (61) 13,093 (47) 4,040 (15) 215 (0.8)
Rhode Island 4,189 (65) 2,375 (37) 599 (9) 45 (0.7)
Wisconsin 5,567 (70) 2,978 (37) 859 (11) 55 (0.7)
* Total percentages exceed 100% because certain patients had multiple symptoms.
† Data represent approximately 60% of reported cases from HP2010 reference states. States did not report data on symptoms for all years during the 15-year 
study period, and one state (New Jersey) did not report any data on symptoms.
§ Erythema migrans.
¶ Data regarding symptoms reported only for 1996.
Discussion
During 1992–2006, the annual number of Lyme disease 
cases reported to CDC increased considerably, while remain-
ing highly focused in northeastern and north-central states. 
Multiple reasons might explain this increase, including a 
true increase in the number of infections, enhanced surveil-
lance, increased awareness among health-care professionals 
and the public, misdiagnosis, and reporting errors (21–23). 
In six HP2010 reference states (Connecticut, Delaware, 
Massachusetts, Maryland, New Jersey, and Rhode Island) in 
which the majority of counties regularly reported cases, a true 
increase in transmission might have resulted from greater tick 
densities and encroachment of human development into rural 
and suburban areas. In other HP2010 reference states, particu-
larly Minnesota, Pennsylvania, and Wisconsin, the number of 
counties reporting cases increased appreciably, suggesting an 
additional role for geographic expansion of reservoir mammals 
and vector ticks into new areas. In certain states, especially those 
in the southeastern United States, Lyme disease surveillance 
is complicated by the occurrence of southern tick-associated 
rash illness, a condition that can resemble early Lyme disease 
but is not caused by B. burgdorferi (24–26).
Overall, features of reported cases changed little over time. 
Peak rates were reported among children, males, and whites 
in each year throughout the 15-year period. However, rates 
increased disproportionately among young males compared 
with young females; the reasons for this difference are not 
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known. The proportion of cases with EM and arthritis, the 
most commonly reported symptoms, has been relatively stable 
since 1993. However, across age categories, the frequency of 
reported symptoms varied widely among persons aged <20 
years, with the lowest percentage of EM (58.2%) and the high-
est percentage of arthritis (38.7%) reported for children aged 
10–14 years. These findings provide a basis for targeting pre-
vention campaigns to populations with increasing incidence.
The findings in this report highlight both the benefits of 
infectious disease surveillance and the opportunity for improve-
ment. Detailed analysis of reported cases enables public health 
authorities to define the demographics and distribution of 
disease and to survey trends. However, growing case counts 
and the implementation of electronic laboratory reporting 
have created a substantial reporting burden on certain state 
and local health departments as they attempt to verify compli-
ance with the surveillance case definition (27,28). This burden 
has caused certain states to curtail or modify portions of their 
surveillance system, resulting in fluctuations in case tallies. In 
2007, CSTE revised the national surveillance case definition 
for Lyme disease with the twin goals of reducing the burden 
of reporting while potentially enhancing the system’s ability to 
capture a broader range of clinical manifestations. The revised 
case definition, which was implemented in January 2008, speci-
fies required laboratory evidence in more detail than previous 
iterations and allows reporting of confirmed and, for the first 
time, probable cases of Lyme disease to CDC (29).
Limitations
The findings in this report are subject to at least three limita-
tions. First, an unknown portion of all Lyme disease cases are 
reported; cases probably are underreported in areas in which 
the disease is endemic and overreported in areas in which the 
disease is not endemic. Misdiagnosis and overreporting from 
areas in which the disease is not endemic might explain the 
demographic differences noted between cases reported from 
HP2010 and non-HP2010 reference states. Second, variation 
in reporting practices and adherence to the surveillance case 
definition occurs among states, in part because states invest 
unequally in infrastructure for Lyme disease surveillance. As 
a result, Lyme disease–specific variables for cases reported by 
certain states are incomplete, unavailable, or not transmitted 
to CDC. Finally, cases are reported on the basis of the patient’s 
state of residence rather than on the state in which the expo-
sure occurred. Therefore, Lyme disease in a traveler returning 
from an area in which the disease is highly endemic cannot be 
construed as evidence of local transmission.
Conclusion
The number of reported cases of Lyme disease continues 
to increase, underscoring the need for targeted prevention 
strategies, early disease recognition and treatment, and a 
sustainable surveillance system. During the 15-year study 
period, incidence increased disproportionately among children, 
particularly males. Geographic expansion was apparent in 
Minnesota, Pennsylvania, and Wisconsin. Differences in the 
features of cases reported from HP2010 reference states and all 
other states suggest either aberrant reporting or fundamental 
differences in the epidemiology of Lyme disease in areas in 
which the disease is not endemic. The percentage of cases for 
which signs of disseminated infection were reported did not 
decrease during the reporting period, underscoring the need 
for continued education about early disease recognition and 
treatment. Despite the limitations of national surveillance data, 
these findings are useful in defining demographics, distribu-
tion, and trends in Lyme disease cases. Intensive surveillance 
methodologies, such as active population-based surveillance 
and the use of nonhuman data (e.g., serologic testing of dogs 
and surveillance for vectors), could be used to augment these 
data and provide a better understanding of this emerging 
infectious disease.
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